Table 4 Baseline characteristics of the patients from randomized controlled trials
Study | Females, n (%) | Age, years, Mean (SD) or Median (range) | Platelet counts per 109/L Mean (SD) or Median (range) | Previous splenectomy, n (%) | Number of previous treatments, n (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | TAs group | Control group | TAs group | Control group | TAs group | Control group | TAs group | Control group | TAs group | Control group |
Bussel et al. 2007 | 73 (62) | 16 (55) | 50 (18–85) | 42 (18–85) | 42 (48)a | 14 (48)a | 41 (47) | 14 (48) | ≥ 3: 60 (51) | ≥ 3: 14 (48) |
Bussel et al. 2009 | 43 (57) | 27 (71) | 47 (19–84) | 51 (21–79) | 38 (50)a | 17 (45)a | 31 (41) | 14 (37) | ≥ 3: 42 (55) | ≥ 3: 16 (42) |
Cheng et al. 2011 | 93 (69) | 43 (69) | 47 (34–56) | 52 (43–63) | 16 (8–22) | 16 (9–24) | 50 (37) | 21 (34) | ≥ 3: 75 (56) | ≥ 3: 32 (52) |
Huang et al. 2018 | 15 (88) | 14 (78) | 50 (24–62) | 40 (22–66) | 14 (4–27) | 14 (1–26) | NA | NA | ≥ 1: 9 (53) | ≥ 1: 7 (39) |
Tomiyama et al. 2012 | 8 (53) | 7 (88) | 58 (26–72) | 61 (38–72) | 21 (16–25) | 10 (8–19) | 11 (73) | 5 (63) | NA | NA |
Yang et al. 2016 | 77 (74) | 40 (78) | 48 (18–84) | 42 (22–66) | 54 (51.9) a | 28 (55) a | 18 (17) | 7 (14) | ≥ 1: 19 (18) | ≥ 1: 10 (20) |
Mei et al. 2021 | 241 (71) | 60 (71) | 41 (18–74) | 42 (18–71) | 13 (1–29) | 13 (1–29) | 29 (9) | 4 (5) | NA | NA |
Bussel et al. 2014 | 37 (63) | 3 (60) | 54 (18) | 40 (21) | 16 (27) | 2 (40) | 18 (31) | 2 (40) | NA | NA |
Jurczak et al. 2018 | 23 (72) | 8 (47) | 46 (14) | 41 (15) | 18 (56) a | 10 (59) a | 11 (34) | 5 (29) | ≥ 1: 15 (47) | ≥ 1: 7 (41) |
Bussel et al. 2006 | 12 (71) | 3 (75) | 45 (19–63) | 55 (39–64) | 15 (4–25) | 29 (6–49) | 13 (76) | 1 (25) | 1–3: 5 (29) 4–6: 9 (53) > 6: 3 (18) | 1–3: 1(25) 4–6: 3 (75) > 6: 0 (0) |
Kuter et al. 2008 | 54 (65) | 27 (64) | 52 (21–88) | 52 (23–88) | 16 (2–29) | 18 (2–31) | 42 (51) | 21 (50) | ≥ 3: 54 (65) | ≥ 3: 26 (60) |
Kuter et al. 2010 | 85 (54) | 46 (60) | 58 (18–90) | 57 (18–86) | 33 (1–123) | 27 (2–62) | 0 (0) | 0 (0) | ≥ 2: 110 (70) | ≥ 2: 60 (78) |
Shirasugi et al. 2011 | 14 (64) | 10 (83) | 59 (13) | 28 (13) | 18 (8) | 16 (1) | 10 (46) | 5 (42) | Median number of treatments: 4 (1–19) | Median number of treatments: 4 (1–7) |
Gu et al. 2013 | 20 (65) | 18 (58) | 52 (22–80) | 48 (21–84) | 7 (1–10) | 7 (1–10) | 0 (0) | 0 (0) | NA | NA |
Wang et al. 2012 | 53 (73) | 33 (52) | 41 (18–74) | 41(18–74) | 11 (2–20) | 10 (1–20) | 9 (12) | 8 (13) | NA | NA |
Yu et al. 2020 | 67 (67) | 65 (68) | 42 (19–74) | 45 (22–73) | 7 (0–24) | 7 (0–30) | 2 (2) | 1 (1) | ≥ 1: 37 (37) | ≥ 1: 44 (46) |
Zhou et al. 2015 | 50 (65) | 25 (66) | 42 (13–82) | 42.5 (12–68) | 9 (0–30) | 13 (2–30) | 9 (12) | 3 (8) | ≥ 1: 43 (57) | ≥ 1: 19 (50) |